IDH2 and neoplasm: While mutations in IDH genes in Acute Myeloid Leukemia have been associated with poor prognosis, the same mutations are considered as markers of improved prognosis in gliomas, indicating interactions with other proteins or the tumour environment may ultimately influence the role of IDH in tumour pathogenesis.